US Pharma MarketingThe funding deal is a vote of confidence in the sales potential of multiple prospects in late-stage development — one of which MeiraGTx recently reacquired from J&J.
Oberland pours up to $400M into MeiraGTx eye gene therapies
The funding deal is a vote of confidence in the sales potential of multiple prospects in late-stage development — one of which MeiraGTx recently reacquired from J&J.
Source: BioPharma Dive